An anti-C3b(i) mAB enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

Blood

Volumn 101, Issue 3, 2003, Pages 1071-1079

  Kennedy, Adam D ^b   Solga, Michael D ^b   Schuman, Theodore A ^b   Chi, Amos W ^b   Lindorfer, Margaret A ^b   Sutherland, William M ^b   Foley, Patricia L ^b   Taylor, Ronald P ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; COMPLEMENT COMPONENT C3B; COMPLEMENT RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3E7; MONOCLONAL ANTIBODY C3B(I); MONOCLONAL ANTIBODY NHS; MONOCLONAL ANTIBODY RTX; RITUXIMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL KILLING; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; MONKEY; NONHUMAN; OPSONIZATION; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; RAJI CELL;

EID: 0037306990     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-03-0876     Document Type: Article

References (59)

1. Walport MJ. Complement. N Engl J Med. 2001;344:1058-1066.
2. Morgan BP, Harris CL. The complement system: a brief overview. In: Morgan BP, Harris CL, eds. Complement Regulatory Proteins. San Diego, CA: Academic Press; 1999:1-31.
3. Volanakis JE. Overview of the complement system. In: Volanakis JE, Frank MM, eds. The Human Complement System in Health and Disease. New York, NY: Marcel Dekker Inc; 1998:9-32.
4. Lambris JD, Sahu A, Wetsel RA. The chemistry and biology of C3, C4 and C5. In: Volanakis JE, Frank MM, eds. The Human Complement System in Health and Disease. New York, NY: Marcel Dekker Inc; 1998:83-119.
5. Sokoloff MH, Nardin A, Solga MD, et al. Targeting of cancer cells with monoclonal antibodies specific for C3b(i). Cancer Immunol Immunother. 2000;49:551-562.
6. Ross GD, Vetvicka V, Yan J, Xia Y, Vetvickova J. Therapeutic intervention with complement and β-glucan in cancer. Immunopharmacology. 1999;42:61-74.
7. Irie K, Irie RF, Morton DL. Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells. Science. 1974;186:454-456.
8. Vetvicka V, Thornton BP, Ross GD. Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest. 1996;98:50-61.
9. Gorter A, Meri S. Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunol Today. 1999;20:576-582.
10. Jurianz K, Ziegler S, Garcia-Schuler H, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol. 1999;36:929-939.
11. Springer GF, Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J Mol Med. 1997;75:594-602.
12. Olesen EH, Johnson AA, Damgraard G, Leslie RGQ. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells. Immunology. 1998;93:177-183.
13. Schwendinger M, Spruth M, Schoch J, Dierich M, Prodinger W. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells. J Immunol. 1997;158:5455-5463.
14. Byrd J, Murphy T, Howard R, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153-2164.
15. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood. 1998;92:1927-1932.
16. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101-106.
17. Grillo-Lopez A, White C, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26:66-73.
18. Czuczman MS, Grillo-Lopez A, Saleh W, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. Clin Oncol. 1999;17:268-276.
19. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
20. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
21. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6:443-446.
22. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med. 1999;134:445-450.
23. Ghetie M, Bright H, Vitetta E. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97:1392-1398.
24. Shan D, Ledbetter J, Press O. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother. 2000;48:673-683.
25. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood. 1998;91:1644-1652.
26. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIa gene. Blood. 2002;99:754-758.
27. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038-1043.
28. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435-445.
29. Idusogie EE, Presta LG, Gazzano-Santoro H, et al. Mapping of the C1q binding site on Rituxan, a chimeric antibody with a human IgG1 Fc. J Immunol. 2000;164:4178-4184.
30. Idusogie EE, Wong PY, Presta LG, etal. Engineered antibodies with increased activity to recruit complement. J Immunol. 2001;166:2571-2575.
31. Harjunpää A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol. 2000;51:634-641.
32. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis. Blood. 2000;95:3900-3908.
33. Flieger D, Renoth S, Beier I, Sauerbrunch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol. 2000;204:55-63.
34. Treon S, Mistsiades C, Mistsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother. 2001;24:263-271.
35. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood. 2001;98:2771-2777.
36. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood. 2001;98:3383-3389.
37. van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, Van Oers MHJ. Complement activations plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115:807-811.
38. Tosic L, Sutherland WM, Kurek J, Edberg JC, Taylor RP. Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose. J Immunol Methods. 1989;120:241-249.
39. Edberg JC, Tosic L, Wright EL, Sutherland WM, Taylor RP. Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes. J Immunol. 1988;141:4258-4265.
40. Fraker PJ, Speck JC. Protein and cell membrane iodinations with a sparingly soluble choloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycol uril. Biochem Biophys Res Commun. 1978;80:849-857.
41. Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1988:354-355.
42. Lindorfer MA, Hahn CS, Foley PL, Taylor RP. Heteropolymer-mediated clearance of immune complexes via erythrocyte CR1: mechanisms and applications. Immunol Rev. 2001;183:10-24.
43. Craig ML, Reinagel ML, Martin EN, et al. Infusion of bispecific monoclonal antibody complexes into monkeys provides immunologic protection against later challenge with a model pathogen. Clin Immunol. 1999;92:170-180.
44. Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J. 1989;264:1-14.
45. Press O, Appelbaum F, Ledbetter J, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood. 1987;69:584-591.
46. Deans JP, Robbins SM, Polyak MJ, Savage JA. Rapid redistribution of CD20 to a low density detergent-insoluble membrane compartment. J Biol Chem. 1998;273:344-348.
47. Stockmeyer B, Dechant M, van Egmond M, et al. Triggering Fcα-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J Immunol. 2000;165:5954-5961.
48. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood. 2001;98:1352-1357.
49. Fishelson Z, Attali G, Mevorach D. Complement and apoptosis. Mol Immunol. 2001;38:207-219.
50. Gadd KJ, Reid KB. The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum. Biochem J. 1981;195:471-480.
51. Brown EJ, Joiner KA, Gaither TA, Hammer CH, Frank MM. The interaction of C3b bound to Pneumococci with factor H (beta 1H globulin), factor I (C3b/C4b inactivator), and properdin factor B of the human complement system. J Immunol. 1983;131:409-415.
52. Vidarte L, Pastor C, Mas S, et al. Serine 132 is the C3 covalent attachment point on the CH1 domain of human IgG1. J Biol Chem. 2001;276:38217-38223.
53. Shohet J, Bergamaschini L, Davis A, Caroll M. Localization of the human complement C3 binding site on the IgG heavy chain. J Biol Chem. 1991;266:18520-18524.
54. Fries LF, Siwik SA, Malbran A, Frank MM. Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leucocytes. Immunology. 1987;62:45-51.
55. Gaither TA, Vargas I, Inada S, Frank MM. The complement fragment C3d facilitates phagocytosis by monocytes. Immunology. 1987;62:405-411.
56. Wallace PK, Valone FH, Fanger MW. Myeloid cell-targeted cytotoxicity of tumor cells. In: Fanger MW, ed. Bispecific Antibodies. Austin, TX: R. G. Landis Co; 1995:43-76.
57. Lugassy G, Platok I, Schlesinger M. Hypocomplementemia in multiple myeloma. Leuk Lymphoma. 1999;33:365-370.
58. Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic patients and in healthy relatives. Leukemia. 1996;10:1509-13.
59. Brezicka T, Einbeigi Z, Bergman B. Functional assessment in vitro of human-complement-dependent antibody-induced cytotoxicity of neoplastic cells. Cancer Immunol Immunother. 2000;49:235-242.